Epigenomics' 2012 Revenues Dip 29 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today said that revenues for full-year 2012 slipped 29 percent.

The German cancer molecular diagnostics company said revenues for the year ended Dec. 31, 2012 totaled €1.0 ($1.3 million), down from €1.4 million in 2011. Revenues resulted from product sales of the company's Epi proColon kits for colorectal cancer testing, royalty payments, and partnering fees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.